Qilian International Holding Group Limited - QLI Total Debt to Capital

Qilian International Holding Group Limited - graphic logo of issuer QLI

The market price action for the individual debt-to-equity ratio of Qilian International (QLI) is visualized for analysis as 0.01. The business procures plant-based components from farmers while maintaining autonomous synthesis at its own facilities. Financial stability is constrained by strict PRC oversight and the volatile cost of antibiotic ingredients. Profits are driven by the export of heparin and licorice, with margins remaining acceptable.

Qilian International Holding (QLI): All Debt to Shareholders' Equity Ratio from 07/04/2022 to 08/17/2024
Finished products of qlsyy.net

This ratio measures the proportion of borrowed funds relative to equity, determining the degree of financial leverage and the risk of default should interest rates rise. Analyzing the debt-to-equity ratio for Qilian International (QLI) is critical, as low margins in chemical production and a lack of pricing power leave the business vulnerable to any excessive debt obligations.

Competitors of Qilian International

HLN (Haleon) - Total Debt to Capital|KVUE: All Debt to Shareholders' Equity Ratio|Total Debt to Capital VRNA|Total Debt to Capital Jyong Bio (MENS)|Debt to Equity Ligand Pharmaceuticals LGND|All Debt to Shareholders' Equity Ratio AMRX|PRGO - Debt to Equity|Alvotech S.A. (ALVO) - Total Debt to Equity Ratio|LQDA: Total Debt to Capital|Galapagos Corp (GLPG) - Total Debt to Capital|Total Debt to Equity Ratio ANIP|MNKD: All Debt to Shareholders' Equity Ratio|Debt to Equity Amphastar Pharmaceuticals, Inc. (AMPH)|PCRX - Debt to Capital|ARS Pharma - Total Debt to Equity Ratio|Aggregate Debt to Capital TBPH (Theravance Corp)|Aquestive Therapeutics - Total Debt to Capital|All Debt to Shareholders' Equity Ratio SCPH (scPharmaceuticals Inc.)|TECX: Total Debt to Capital|Debt to Capital Tonix Pharma (TNXP)|Debt to Equity SXT Pharmaceuticals|EPRX: All Debt to Shareholders' Equity Ratio|Debt to Equity BioHarvest Sciences (BHST)|invizyne.com (EXOZ) - Debt to Capital Ratio|Total Debt to Capital ORMP (Oramed Pharmaceuticals Inc.)|Total Debt to Capital Coefficient Entera Bio Ltd (ENTX)|HYFT - Debt to Equity|ABVC: Debt to Equity|CPIX: Total Debt to Capital|QNTM - Total Debt to Capital Coefficient|FGEN (FibroGen) - Total Debt to Capital|Total Debt to Capital Telomir Pharmaceuticals Inc|Debt to Equity Rani Therapeutics (RANI)|synergychc.com - Debt to Equity Ratio|Rallybio - Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio LEXX|Pulmatrix - Total Debt to Capital|Total Debt to Capital Coefficient Pheton Holdings Ltd PTHL|aptorumgroup.com (APM) - Debt to Equity|Debt to Equity Ratio LYRA|Total Debt to Equity Ratio IBO|TNFA (TNF Pharma) - Aggregate Debt to Capital|Total Debt to Capital YCBD|PRFX - Debt to Capital|Debt to Equity Altamira Therapeutics Ltd. CYTO|All Debt to Shareholders' Equity Ratio LIPO|OPTN - Debt to Equity|PIRS (pieris.com) - Debt to Equity Ratio|PROC: Total Debt to Capital|Petros Pharmaceuticals Inc (PTPI) - Total Debt to Capital|Total Debt to Equity Ratio SLRN|TFFP (TFF Pharmaceuticals, Inc) - Aggregate Debt to Capital